- Home
- TOVX vs CNSP Comparison
TOVX vs CNSP Comparison
Compare TOVX & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOVX
- CNSP
- Stock Information
- Founded
- TOVX 2001
- CNSP 2017
- Country
- TOVX United States
- CNSP United States
- Employees
- TOVX N/A
- CNSP N/A
- Industry
- TOVX Biotechnology: Pharmaceutical Preparations
- CNSP Biotechnology: Pharmaceutical Preparations
- Sector
- TOVX Health Care
- CNSP Health Care
- Exchange
- TOVX Nasdaq
- CNSP Nasdaq
- Market Cap
- TOVX 4.7M
- CNSP 5.6M
- IPO Year
- TOVX 2006
- CNSP 2019
- Fundamental
- Price
- TOVX $1.18
- CNSP $1.13
- Analyst Decision
- TOVX Strong Buy
- CNSP Hold
- Analyst Count
- TOVX 1
- CNSP 1
- Target Price
- TOVX $6.00
- CNSP N/A
- AVG Volume (30 Days)
- TOVX 23.5K
- CNSP 323.7K
- Earning Date
- TOVX 05-06-2025
- CNSP 05-14-2025
- Dividend Yield
- TOVX N/A
- CNSP N/A
- EPS Growth
- TOVX N/A
- CNSP N/A
- EPS
- TOVX N/A
- CNSP N/A
- Revenue
- TOVX N/A
- CNSP N/A
- Revenue This Year
- TOVX N/A
- CNSP N/A
- Revenue Next Year
- TOVX N/A
- CNSP N/A
- P/E Ratio
- TOVX N/A
- CNSP N/A
- Revenue Growth
- TOVX N/A
- CNSP N/A
- 52 Week Low
- TOVX $1.03
- CNSP $1.10
- 52 Week High
- TOVX $12.25
- CNSP $800.00
- Technical
- Relative Strength Index (RSI)
- TOVX 44.04
- CNSP 29.26
- Support Level
- TOVX $1.08
- CNSP $1.28
- Resistance Level
- TOVX $1.21
- CNSP $1.46
- Average True Range (ATR)
- TOVX 0.07
- CNSP 0.34
- MACD
- TOVX 0.00
- CNSP -0.11
- Stochastic Oscillator
- TOVX 57.89
- CNSP 0.86
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.
About CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.